Elimination of post-transplant donor-specific HLA antibodies with bortezomib
| Autor: | A, Idica, H, Kaneku, M J, Everly, H L, Trivedi, A, Feroz, A V, Vanikar, V, Shankar, V B, Trivedi, P R, Modi, S I, Khemchandani, S D, Dave, P I, Terasaki |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Graft Rejection Male Time Factors Plasma Cells Plasmapheresis Middle Aged Boronic Acids Kidney Transplantation Antibodies Bortezomib Young Adult Treatment Outcome HLA Antigens Pyrazines Living Donors Humans Transplantation Homologous Protease Inhibitors Proteasome Inhibitors Immunosuppressive Agents |
| Zdroj: | Clinical transplants. |
| ISSN: | 0890-9016 |
| Popis: | We show the ability of bortezomib to remove donor-specific HLA antibody from kidney allograft patients, the drug acting as a proteasome inhibitor, providing targeted therapy against antibody-producing plasma cells. Ten out of thirteen patients (77%) experienced primary DSA reversal, and in the remaining three patients the MFI of their primary DSA was dramatically reduced. Bortezomib is a viable therapy to treat donor-specific HLA antibody in allograft recipients. The potential for long-term benefits--and complications--are still unknown. Prospective trials are being conducted at the University of Cincinnati, Cincinnati, OH; at the Mayo Clinic, Rochester, MN; and at IKDRC-ITS, Ahmedabad, India. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|